Halper Sadeh Investigates Twist Bioscience Board for Fiduciary Breaches
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 6 hour ago0mins
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Twist Bioscience breached their fiduciary duties, which could impact the company's governance structure and shareholder trust.
- Legal Relief Options: Long-term shareholders of Twist stock may seek corporate governance reforms, fund recovery, or court-approved financial incentives, potentially improving management and transparency within the company.
- Importance of Shareholder Participation: Shareholder involvement can drive improvements in company policies and oversight mechanisms, thereby enhancing transparency and accountability, ultimately increasing shareholder value.
- Legal Fee Arrangement: The law firm will handle the case on a contingency fee basis, meaning shareholders will not incur out-of-pocket legal expenses, reducing the financial burden of participation and encouraging more shareholders to engage in advocacy.
TWST.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on TWST
Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 38.00 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.120
Low
32.00
Averages
38.00
High
42.00
Current: 32.120
Low
32.00
Averages
38.00
High
42.00
Barclays
Overweight
downgrade
$40 -> $37
2025-11-17
Reason
Barclays
Price Target
$40 -> $37
2025-11-17
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Twist Bioscience to $37 from $40 and keeps an Overweight rating on the shares. The firm says management's description of being "commercially violent" continues to win market share. However, questions on Twist's market opportunities remain, particularly in synthetic biology, the analyst tells investors in a research note.
Stephens
Steven Etoch
Overweight
initiated
$41
2025-11-03
Reason
Stephens
Steven Etoch
Price Target
$41
2025-11-03
initiated
Overweight
Reason
Stephens analyst Steven Etoch initiated coverage of Twist Bioscience with an Overweight rating and $41 price target. Twist operates a differentiated, technology-driven DNA synthesis platform with proprietary silicon chip technology, inspired by semiconductor manufacturing, that provides advantages in cost, speed, and scale. While competition remains intense, Twist's cost leadership and prior investments are driving share gains and although the path to profitability is "not fully de-risked," the firm sees a growing line of sight driven by strategic execution and commercial momentum, the analyst tells investors.
Evercore ISI
Outperform
downgrade
$50 -> $46
2025-08-04
Reason
Evercore ISI
Price Target
$50 -> $46
2025-08-04
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Twist Bioscience to $46 from $50 and keeps an Outperform rating on the shares. The firm updated the company's model post the fiscal Q3 report. It views the quarter as "decent" with solid gross margins. Twist has solid momentum entering fiscal 2026, the analyst tells investors in a research note.
TD Cowen
Brendan Smith
Buy
downgrade
$58 -> $36
2025-08-04
Reason
TD Cowen
Brendan Smith
Price Target
$58 -> $36
2025-08-04
downgrade
Buy
Reason
TD Cowen analyst Brendan Smith lowered the firm's price target on Twist Bioscience to $36 from $58 and keeps a Buy rating on the shares. The stock has been under pressure following Q3 revenue that was in line with guidance and the narrowing of FY25 guidance as investor hoped for "a clean beat/raise." The firm, which is trimming near-term estimstes for SynBio, largely offset by consistent NGS growth into next year, now assigns a multiple closer to peer trading multiples to reflect updated growth assumptions.
See All Ratings
About TWST
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key allegations against Twist Bioscience in the lawsuit?
How does Kuehn Law aim to protect shareholder rights in this case?
How might the financial fraud allegations impact Twist Bioscience's market value?
Will the new plasmid DNA preps improve Twist Bioscience's customer retention rates?